PerkinElmer’s EUROIMMUN Presents Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics
|
By LabMedica International staff writers Posted on 21 Jun 2021 |

Image: EUROPattern Microscope Live (Photo courtesy of PerkinElmer, Inc.)
EUROIMMUN, a PerkinElmer, Inc. (Waltham, MA; USA) company, presented its novel ultrafast automated microscope and intelligent software for state-of-the-art diagnostics at Medlab Middle East 2021.
The company’s portfolio encompasses indirect immunofluorescence assays (IFA), ELISAs, immunoblots, radioimmunoassays, chemiluminescence immunoassays (ChLIA) and molecular genetic test systems and spans over a thousand diagnostic parameters. At this year’s edition of Medlab Middle East, EUROIMMUN introduced its newly-launched EUROPattern Microscope Live (EPML), a compact immunofluorescence microscope available with the fourth generation of the company’s well-established EUROLabOffice 4.0 (ELO 4.0) laboratory management software. The combined system of hardware and software allows for ultrafast automated immunofluorescence image acquisition, pattern recognition and titer estimation as well as modern diagnostics at the screen.
Due to application of a novel laser focusing technology, the EPML acquires and interprets high quality immunofluorescence images in less than two seconds per image. The system autonomously evaluates a particularly high number of recorded immunofluorescence patterns that are indicative of the presence of certain autoantibodies, and thus point to a specific autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, vasculitis or autoimmune hepatitis. In addition to the positive/negative classification for a variety of different substrates, the patterns of anti-nuclear antibodies (in conformity with the International Consensus on Antinuclear Antibody Patterns) and anti-neutrophil cytoplasmic antibodies can also be recognized by leveraging deep learning algorithms. A touch screen allows easy live microscopy via multi-touch navigation and pinch-to-zoom functionality.
ELO 4.0 software further simplifies and is designed to speed up not only IIFT testing but also other laboratory diagnostics by acting as the central interface for all laboratory instruments, working places and laboratory information systems. ELO 4.0 software enables intelligent and intuitive data management as well as the seamless communication needed to provide operators with a 360-degree view of a patient’s results, including current and past findings, that can lead to a faster, more reliable diagnosis.
In addition, EUROIMMUN showcased its comprehensive test and automation portfolio of CE-marked tests for direct and indirect detection of SARS-CoV-2, including its PCR-based tests EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2 / Influenza A / B as well as the SARS-CoV-2 Antigen ELISA.
Related Links:
PerkinElmer, Inc.
The company’s portfolio encompasses indirect immunofluorescence assays (IFA), ELISAs, immunoblots, radioimmunoassays, chemiluminescence immunoassays (ChLIA) and molecular genetic test systems and spans over a thousand diagnostic parameters. At this year’s edition of Medlab Middle East, EUROIMMUN introduced its newly-launched EUROPattern Microscope Live (EPML), a compact immunofluorescence microscope available with the fourth generation of the company’s well-established EUROLabOffice 4.0 (ELO 4.0) laboratory management software. The combined system of hardware and software allows for ultrafast automated immunofluorescence image acquisition, pattern recognition and titer estimation as well as modern diagnostics at the screen.
Due to application of a novel laser focusing technology, the EPML acquires and interprets high quality immunofluorescence images in less than two seconds per image. The system autonomously evaluates a particularly high number of recorded immunofluorescence patterns that are indicative of the presence of certain autoantibodies, and thus point to a specific autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, vasculitis or autoimmune hepatitis. In addition to the positive/negative classification for a variety of different substrates, the patterns of anti-nuclear antibodies (in conformity with the International Consensus on Antinuclear Antibody Patterns) and anti-neutrophil cytoplasmic antibodies can also be recognized by leveraging deep learning algorithms. A touch screen allows easy live microscopy via multi-touch navigation and pinch-to-zoom functionality.
ELO 4.0 software further simplifies and is designed to speed up not only IIFT testing but also other laboratory diagnostics by acting as the central interface for all laboratory instruments, working places and laboratory information systems. ELO 4.0 software enables intelligent and intuitive data management as well as the seamless communication needed to provide operators with a 360-degree view of a patient’s results, including current and past findings, that can lead to a faster, more reliable diagnosis.
In addition, EUROIMMUN showcased its comprehensive test and automation portfolio of CE-marked tests for direct and indirect detection of SARS-CoV-2, including its PCR-based tests EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2 / Influenza A / B as well as the SARS-CoV-2 Antigen ELISA.
Related Links:
PerkinElmer, Inc.
Latest MEDLAB 2021 News
- Ortho Exhibits VITROS Range of Diagnostic Testing and Automation Solutions at MEDLAB Middle East 2021
- MP Biomedicals Exhibits Diagnostics Kits and Sample Prep Solutions at MEDLAB Middle East 2021
- BD Demonstrates Latest Medtech Innovations at MEDLAB Middle East 2021
- Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021
- Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021
- Horiba Medical Exhibits New Generation of Automated Hematology Analyzers at MEDLAB Middle East 2021
- Rad Source Technologies Introduces Premier X-Ray Blood Irradiator RS 3400 at MEDLAB Middle East 2021
- Nova Biomedical Showcases Advanced Point-of-Care Capillary Blood Analyzers at MEDLAB Middle East 2021
- Erba Mannheim Showcases Exciting New Introductions at MEDLAB Middle East 2021
- Bioperfectus Presents Advanced Infectious Disease Diagnostic Solutions at MEDLAB Middle East 2021
- PerkinElmer Demonstrates High-Throughput MSMS Dried Blood Spot Screening Solutions at Medlab Middle East 2021
- LumiraDx Highlights Next-Generation Point of Care Solutions at MEDLAB Middle East Virtual Event
- Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021
- MEDLAB Middle East 2021 Brings World of Laboratory Medicine Together Under ‘United by Business’ Show Theme
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read moreMolecular Diagnostics
view channel
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more
Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









